Rosetta Genomics Stock Return On Asset

Rosetta Genomics fundamentals help investors to digest information that contributes to Rosetta Genomics' financial success or failures. It also enables traders to predict the movement of Rosetta Stock. The fundamental analysis module provides a way to measure Rosetta Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rosetta Genomics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Rosetta Return On Asset Analysis

Rosetta Genomics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Rosetta Genomics Return On Asset

    
  -60.19  
Most of Rosetta Genomics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rosetta Genomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition
Based on the latest financial disclosure, Rosetta Genomics has a Return On Asset of -60.19. This is much higher than that of the sector and notably higher than that of the Return On Asset industry. The return on asset for all United States stocks is notably higher than that of the company.

Rosetta Return On Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rosetta Genomics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rosetta Genomics could also be used in its relative valuation, which is a method of valuing Rosetta Genomics by comparing valuation metrics of similar companies.
Rosetta Genomics is currently under evaluation in return on asset category among related companies.

Rosetta Fundamentals

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Rosetta Genomics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Rosetta Genomics' short interest history, or implied volatility extrapolated from Rosetta Genomics options trading.

Currently Active Assets on Macroaxis

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Rosetta Stock

If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Commodity Directory
Find actively traded commodities issued by global exchanges
CEOs Directory
Screen CEOs from public companies around the world
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine